| 2.1 0.12 (6.06%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.67  |
1-year : | 3.12 |
| Resists | First : | 2.28 |
Second : | 2.67 |
| Pivot price | 2.05 |
|||
| Supports | First : | 1.96 |
Second : | 1.75 |
| MAs | MA(5) : | 2.08 |
MA(20) : | 2.01 |
| MA(100) : | 3.12  |
MA(250) : | 2.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.5 |
D(3) : | 62.8 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 6.28 | Low : | 1.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRSN ] has closed below upper band by 40.1%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.12 - 2.13 | 2.13 - 2.14 |
| Low: | 1.96 - 1.97 | 1.97 - 1.98 |
| Close: | 2.08 - 2.1 | 2.1 - 2.12 |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Jul 2024
Acadian Asset Management LLC Acquires 293,115 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Thu, 25 Jul 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock Holdings Boosted by Acadian Asset Management LLC - Defense World
Wed, 24 Jul 2024
BNP Paribas Financial Markets Increases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Wed, 19 Jun 2024
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Sun, 12 May 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Thu, 09 May 2024
Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 122 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 9,680 (K) |
| Shares Short P.Month | 11,060 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | 0 % |
| Operating Margin | -227.2 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -292.2 % |
| Qtrly Rev. Growth | 18.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -173 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -1.88 |
| PEG Ratio | 0 |
| Price to Book value | 9.13 |
| Price to Sales | 6.7 |
| Price to Cash Flow | -1.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|